Literature DB >> 10769290

Endothelial cell activation by pore-forming structures: pivotal role for interleukin-1alpha.

S Saadi1, R A Holzknecht, C P Patte, J L Platt.   

Abstract

BACKGROUND: Interaction of complement with endothelial cells (ECs) underlies the development of inflammation and coagulation in disease. Assembly of the membrane attack complex (MAC) of complement on EC membrane, like stimulation with cytokines, upregulates tissue factor and cyclooxygenase-2 but does so via the intermediary action of IL-1alpha. We asked whether the MAC activates porcine aortic and microvascular ECs in a global manner by this mechanism and whether this mechanism is used by membrane pore-forming structures. METHODS AND
RESULTS: Exposure of ECs to complement caused upregulation of mRNAs for E-selectin, intracellular adhesion molecule-1, vascular cell adhesion molecule-1, Ikappa-Balpha, interleukin (IL)-1alpha, IL-1beta, IL-8, and plasminogen activator inhibitor-1 over a period of 6 hours. The expression of these genes was not a primary response to stimulation, however, because IL-1 receptor antagonist inhibited expression of these genes. Activation of ECs by complement depended on the autocrine action of IL-1alpha, because complement-mediated EC activation was inhibited by anti-IL-1alpha antibodies. Melittin and mastoparan, amphiphilic pore-forming peptides like the MAC, induced E-selectin through intermediary action of IL-1.
CONCLUSIONS: These findings suggest that transmembrane pore-forming proteins, as a class of molecules, activate ECs through the autocrine effects of IL-1alpha.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10769290     DOI: 10.1161/01.cir.101.15.1867

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  27 in total

1.  Classical pathway complement activation on human endothelial cells.

Authors:  Wei Yin; Berhane Ghebrehiwet; Babette Weksler; Ellinor I Peerschke
Journal:  Mol Immunol       Date:  2006-12-14       Impact factor: 4.407

2.  Current status of animal-to-human transplantation.

Authors:  Robert Zhong; Jeffrey L Platt
Journal:  Expert Opin Biol Ther       Date:  2005-11       Impact factor: 4.388

3.  The mannose-binding lectin pathway is a significant contributor to reperfusion injury in the type 2 diabetic heart.

Authors:  Laura R La Bonte; Betsy Dokken; Grace Davis-Gorman; Gregory L Stahl; Paul F McDonagh
Journal:  Diab Vasc Dis Res       Date:  2009-07       Impact factor: 3.291

4.  Ulex europaeus agglutinin II (UEA-II) is a novel, potent inhibitor of complement activation.

Authors:  R Lekowski; C D Collard; W R Reenstra; G L Stahl
Journal:  Protein Sci       Date:  2001-02       Impact factor: 6.725

Review 5.  The role of complement activation in atherosclerosis.

Authors:  Florin Niculescu; Horea Rus
Journal:  Immunol Res       Date:  2004       Impact factor: 2.829

Review 6.  Tissue factor in antiphospholipid antibody-induced pregnancy loss: a pro-inflammatory molecule.

Authors:  G Girardi; N Mackman
Journal:  Lupus       Date:  2008-10       Impact factor: 2.911

Review 7.  New concepts of complement in allorecognition and graft rejection.

Authors:  Barbara A Wasowska; Chih-Yuan Lee; Marc K Halushka; William M Baldwin
Journal:  Cell Immunol       Date:  2007-10-24       Impact factor: 4.868

8.  Constitutive repression of interleukin-1alpha in endothelial cells.

Authors:  Gregory J Brunn; Soheyla Saadi; Jeffrey L Platt
Journal:  Circ Res       Date:  2008-02-21       Impact factor: 17.367

Review 9.  Complement Membrane Attack Complex: New Roles, Mechanisms of Action, and Therapeutic Targets.

Authors:  Catherine B Xie; Dan Jane-Wit; Jordan S Pober
Journal:  Am J Pathol       Date:  2020-03-16       Impact factor: 4.307

Review 10.  Heparan Sulfate Proteoglycan Metabolism and the Fate of Grafted Tissues.

Authors:  Jeffrey L Platt; Lucile E Wrenshall; Geoffrey B Johnson; Marilia Cascalho
Journal:  Adv Exp Med Biol       Date:  2015       Impact factor: 2.622

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.